Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Axsome Therapeutics (AXSM) Operating Expenses (2022 - 2025)

Axsome Therapeutics' Operating Expenses history spans 4 years, with the latest figure at $223.0 million for Q4 2025.

  • For Q4 2025, Operating Expenses rose 16.5% year-over-year to $223.0 million; the TTM value through Dec 2025 reached $805.3 million, up 20.86%, while the annual FY2025 figure was $805.3 million, 20.86% up from the prior year.
  • Operating Expenses for Q4 2025 was $223.0 million at Axsome Therapeutics, up from $217.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $223.0 million in Q4 2025 and bottomed at $38.3 million in Q1 2022.
  • The 4-year median for Operating Expenses is $153.7 million (2024), against an average of $137.7 million.
  • The largest annual shift saw Operating Expenses soared 163.65% in 2023 before it increased 12.71% in 2024.
  • A 4-year view of Operating Expenses shows it stood at $84.3 million in 2022, then surged by 101.45% to $169.8 million in 2023, then increased by 12.71% to $191.4 million in 2024, then grew by 16.5% to $223.0 million in 2025.
  • Per Business Quant, the three most recent readings for AXSM's Operating Expenses are $223.0 million (Q4 2025), $217.1 million (Q3 2025), and $186.8 million (Q2 2025).